Drug may prevent headaches from medication overuse
The drug erenumab may help patients with chronic migraines achieve remission of medication overuse headaches.
Erenumab is a calcitonin gene-related peptide receptor monoclonal antibody.
In a phase IV trial published in JAMA Neurology, researchers randomly assigned 584 adult patients with chronic migraines and nonopioid medication overuse headaches to receive monthly, subcutaneous injections of erenumab at one of two dose levels (70 mg or 140 mg) or placebo.
After a follow-up of six months, the researchers found that the highest dose of erenumab was the most effective at inducing medicine overuse headache remission compared with the lower erenumab dose and placebo. Further, use of erenumab reduced acute headache medication days.
The researchers reported that the most common adverse events in the erenumab group included constipation and COVID-19 infections.
The findings provided American Academy of Neurology class I evidence of the preventive effects of erenumab in this patient population.
Read more: JAMA Neurology
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.